Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
The distribution of the newly characterized peptide somatostatin-28(1-12) was determined in rat tissues using a radioimmunoassay in which the immune plasma is directed against the C-terminus of the dodecapeptide. In the central nervous system, somatostatin-28(1-12)-like immunoreactivity is highly concentrated in the hypothalamus and the amygdala. In the digestive system, the highest levels of immunoreactivity are found in the stomach, the pancreas and the colon. The immunoreactive material measured in different tissues is the heterogenous: in addition to the dodecapeptide, two N-terminally extended somatostatin-28(1-12) peptides of 4,400 and 8,000 mol wt are also detected by the immune plasma. However, the dodecapeptide itself usually accounts for the majority (66 to 75%) of the total somatostatin-28(1-12)-like immunoreactivity present in those tissues.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1210/endo-111-6-2149 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!